Difference between revisions of "Tebentafusp (Kimmtrak)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2022-01-25: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic [[uveal melanoma]]. ''(Based on IMCgp100-202)'' |
| − | + | ==History of changes in EMA indication== | |
| + | *2022-04-01: Initial authorization as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic [[uveal melanoma]]. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' IMC-gp100 |
*'''Generic name:''' tebentafusp-tebn | *'''Generic name:''' tebentafusp-tebn | ||
*'''Brand name:''' Kimmtrak | *'''Brand name:''' Kimmtrak | ||
| Line 18: | Line 19: | ||
[[Category:Immunotherapeutic]] | [[Category:Immunotherapeutic]] | ||
| + | [[Category:EMA approved in 2022]] | ||
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] | ||
Latest revision as of 00:43, 29 July 2023
Mechanism of action
Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.
Diseases for which it is used
History of changes in FDA indication
- 2022-01-25: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. (Based on IMCgp100-202)
History of changes in EMA indication
- 2022-04-01: Initial authorization as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Also known as
- Code name: IMC-gp100
- Generic name: tebentafusp-tebn
- Brand name: Kimmtrak